Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Small Lymphocytic Lymphoma
Related studies linked through entity extraction aliases.
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- Status
- RECRUITING
- Phase
- PHASE2
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE1
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
Mosunetuzumab for CLL MRD Clearance
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
- Status
- RECRUITING
- Phase
- PHASE2
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE3
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Status
- RECRUITING
- Phase
- PHASE3
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
- Status
- RECRUITING
- Phase
- NA
A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- Status
- RECRUITING
- Phase
- N/A
64Cu-LLP2A for Imaging Hematologic Malignancies
- Status
- RECRUITING
- Phase
- EARLY_PHASE1